Zacks Research Equities Analysts Lift Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Research analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a report issued on Monday, September 16th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings of $0.27 per share for the quarter, up from their prior estimate of $0.26. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.10 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.31 EPS, Q3 2025 earnings at $0.36 EPS, Q4 2025 earnings at $0.44 EPS, FY2025 earnings at $1.38 EPS and Q2 2026 earnings at $0.53 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Monday, July 29th. The biotechnology company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.09. The business had revenue of $163.80 million during the quarter, compared to the consensus estimate of $155.14 million. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The business’s quarterly revenue was up 39.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.25 EPS.

Other analysts have also recently issued reports about the company. HC Wainwright upped their target price on Corcept Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. Piper Sandler upped their target price on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday. Canaccord Genuity Group restated a “buy” rating and issued a $38.00 target price on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Finally, Truist Financial reiterated a “buy” rating and set a $65.00 price target on shares of Corcept Therapeutics in a report on Monday, June 17th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics has a consensus rating of “Buy” and an average price target of $53.75.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $40.92 on Thursday. The business has a fifty day moving average price of $35.16 and a 200 day moving average price of $29.86. Corcept Therapeutics has a one year low of $20.84 and a one year high of $43.74. The company has a market cap of $4.26 billion, a P/E ratio of 38.60 and a beta of 0.45.

Insider Transactions at Corcept Therapeutics

In other news, insider Joseph Douglas Lyon sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $32.49, for a total transaction of $162,450.00. Following the sale, the insider now owns 9,290 shares of the company’s stock, valued at approximately $301,832.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Joseph Douglas Lyon sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $32.49, for a total transaction of $162,450.00. Following the transaction, the insider now owns 9,290 shares in the company, valued at approximately $301,832.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $32.81, for a total value of $72,182.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,451 shares of company stock valued at $1,090,844. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in shares of Corcept Therapeutics by 90.6% in the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 579 shares in the last quarter. Park Place Capital Corp purchased a new stake in shares of Corcept Therapeutics in the second quarter valued at approximately $32,000. Atwood & Palmer Inc. purchased a new stake in shares of Corcept Therapeutics in the second quarter valued at approximately $35,000. FinTrust Capital Advisors LLC boosted its stake in shares of Corcept Therapeutics by 318.7% in the first quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 1,348 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in shares of Corcept Therapeutics by 27.0% in the fourth quarter. Quadrant Capital Group LLC now owns 2,107 shares of the biotechnology company’s stock valued at $68,000 after buying an additional 448 shares in the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.